Fig. 1

GLP-1R antagonist exendin-3 (Ex-3) abolished the effect of DPP-4i sitagliptin (SG) on GLP-1 expression in lung tissues (a), right ventricular systolic pressure (RVSP) (b), pulmonary arterial wall thickness (PAWT) (c), weight gain during the 4 weeks (ΔWeight) (d), and on the ratio of RV to LV + S (e), as well as on the hypertrophy of cardiomyocytes [cross section area (CSA) of cardiomyocytes] (f). Data were presented as the mean ± s.e.m. (n = 6–8). *P < 0.05, **P < 0.01, ***P < 0.001. DPP-4i, Dipeptidyl peptidase IV inhibitor; GLP-1, glucagon-like peptide-1; GLP-1R, GLP-1 receptor; RV, right ventricle; LV + S, left ventricle + interventricular septum